More on Sequestration and the FDA Budget for FY 13

An article on Bloomberg Businessweek this morning offers additional information on the potential threat that sequestration presents to the FDA's budge for 2013.Entitled "FDA drug review deal set to unravel as fiscal cliff looms," the article includes comments from Karen Riley at the FDA, from Steven Grossman of the Alliance, and from Alan Goldhammer (an independent pharmaceutical industry consultant).